Supernus Pharmaceuticals Inc. (SUPN)

factsheet Factsheet
  • Market Capitalisation market-capitalisation-info $1,827 Mln
  • Price to Earnings Ratio price-to-earning 37.26
  • 12 Month Earnings monthly-earning $52 Mln

Supernus Pharmaceuticals Inc. (SUPN) Share Price

$28.11

As on 04-Dec-2023 16:00 EST

up-down-arrow $0.531.92%

  • Prev Close info

    $27.58

  • Day's Openinfo

    $27.65

  • Today's Highinfo

    $28.30

  • Today's Lowinfo

    $27.60

  • Today's Volumeinfo

    353,259

  • 52 Week rangeinfo

    $21.99 - 42.09

Please wait...

Supernus Pharmaceuticals Inc. (SUPN) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Supernus Pharmaceuticals (SUPN)
-21.19 14.83 -13.48 -25.06 8.91 -10.47 15.00
S&P BSE Sensex*
13.81 7.58 5.51 10.14 15.38 13.89 12.83
S&P BSE Healthcare#
32.52 9.96 9.78 27.57 13.32 16.60 12.24
As on 04-Dec-2023  |  *As on 05-Dec-2023  |  #As on 05-Dec-2023
2022
2021
2020
2019
2018
2017
2016
Supernus Pharmaceuticals (SUPN)
22.33 15.90 6.07 -28.60 -16.55 57.82 87.87
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91 1.95
S&P BSE Healthcare
-12.10 20.87 61.45 -3.55 -5.89 0.49 -12.88

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Supernus Pharmaceuticals Inc. (SUPN) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Supernus Pharmaceuticals Inc. (SUPN)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Supernus Pharmaceuticals Inc. (SUPN)

        Founder, Pres, CEO, Sec. & Director

        Mr. Jack A. Khattar

        Sr. VP & CFO

        Mr. Timothy C. Dec

        Headquarters

        Rockville, MD

        FAQs for Supernus Pharmaceuticals Inc. (SUPN)

        The total asset value of Supernus Pharmaceuticals Inc. (SUPN) stood at $ 2,523 Mln as on 31-Mar-23

        The share price of Supernus Pharmaceuticals Inc. (SUPN) is $28.11 (NASDAQ) as of 04-Dec-2023 16:00 EST. Supernus Pharmaceuticals Inc. (SUPN) has given a return of 8.91% in the last 3 years.

        Supernus Pharmaceuticals Inc. (SUPN) has a market capitalisation of $ 1,827 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

        The P/B ratio of Supernus Pharmaceuticals Inc. (SUPN) is 2.23 times as on 02-Jun-2023, a -0.21% premium to its peers’ median range of 2.82 times.

        The P/E ratio of Supernus Pharmaceuticals Inc. (SUPN) is 37.26 times as on 02-Jun-2023, a 0.71% premium to its peers’ median range of 21.83 times.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Supernus Pharmaceuticals Inc. (SUPN) and enter the required number of quantities and click on buy to purchase the shares of Supernus Pharmaceuticals Inc. (SUPN).

        Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

        The CEO & director of Mr. Jack A. Khattar. is Supernus Pharmaceuticals Inc. (SUPN), and CFO & Sr. VP is Mr. Timothy C. Dec.

        The promoters of Supernus Pharmaceuticals Inc. (SUPN) have pledged 0% of the total equity as on Dec-22.

        Supernus Pharmaceuticals Inc. (SUPN) Ratios
        Return on equity(%)
        5.9
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        Yes, TTM profit after tax of Supernus Pharmaceuticals Inc. (SUPN) was $52 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $1,826.59 Mln
        • Revenue (TTM)revenue-information $668.50 Mln
        • Earnings (TTM) earning-information $52.04 Mln
        • Cash date-information $228.57 Mln
        • Total Debt info $517.37 Mln
        • Insider's Holding 4.94%
        • Liquidity liquidity High
        • 52 Week range week-range $21.99 - 42.09
        • Shares outstanding share-outstanding 54,476,400
        • 10 Years Aggregate:

          CFO: $817.83 Mln

          EBITDA: $942.92 Mln

          Net Profit: $555.25 Mln

        About The Company

        • IPO Date 01-May-2012
        • Founder, Pres, CEO, Sec. & Director Mr. Jack A. Khattar
        • Sr. VP & CFO Mr. Timothy C. Dec
        • Listing key-listing NASDAQ: SUPN
        • Country United States
        • Headquarters headquarters Rockville, MD
        • Website website https://www.supernus.com
        • Business

          Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an...  extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon